• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>日本臨牀 >Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C
【24h】

Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C

机译：乳铁蛋白抗慢性丙型肝炎的基础研究和临床应用的最新进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatitis C virus(HCV), discovered in 1989, is the major causative agent of chronic viral hepatitis. Most patients progress to liver cirrhosis and hepatocellular carcinoma. In the therapy of hepatitis C, only interferon has been used effectively as an anti-HCV reagent in Japan, but its effectiveness is limited to about 30% of cases. Using human hepatocyte cell line which could support efficient HCV replication, we previously found that lactoferrin inhibited HCV infection, and demonstrated that this inhibiting activity was due to the interaction of lactoferrin with HCV. Further analysis found that the carboxyl region of lactoferrin, which partially shows amino acid sequence homology to human CD81, specifically bound to the HCV E2 envelope protein, and identified a 33 amino acids as a critical binding domain of lactoferrin. On the other hand, it has been shown that bovine lactoferrin was effective in some patients with chronic hepatitis received an 8-week course of lactoferrin treatment. Further clinicaltrials showed that lactoferrin is a promising candidate for adjuvant therapy with interferon in patients with chronic hepatitis C.
机译：丙型肝炎病毒（HCV）于1989年发现，是慢性病毒性肝炎的主要病原体。大多数患者进展为肝硬化和肝细胞癌。在丙型肝炎的治疗中，在日本只有干扰素被有效地用作抗HCV试剂，但其有效性仅限于约30％的病例。使用可以支持有效HCV复制的人肝细胞系，我们先前发现乳铁蛋白抑制HCV感染，并证明这种抑制活性是由于乳铁蛋白与HCV的相互作用所致。进一步的分析发现，乳铁蛋白的羧基部分显示与人CD81的氨基酸序列同源性，与HCV E2包膜蛋白特异性结合，并鉴定出33个氨基酸是乳铁蛋白的关键结合域。另一方面，已经证明牛乳铁蛋白在一些接受了乳铁蛋白治疗的8周疗程的慢性肝炎患者中是有效的。进一步的临床试验表明，乳铁蛋白对于慢性丙型肝炎患者是干扰素辅助治疗的有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号